New Zealand markets close in 4 hours 48 minutes

Caribou Biosciences, Inc. (CRBU)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.81-0.10 (-1.45%)
At close: 04:00PM EST
6.70 -0.11 (-1.62%)
After hours: 05:20PM EST
Full screen
Trade prices are not sourced from all markets
Previous close6.91
Open6.80
Bid6.77 x 1100
Ask6.74 x 1000
Day's range6.66 - 6.95
52-week range3.44 - 8.59
Volume760,408
Avg. volume1,606,148
Market cap602.216M
Beta (5Y monthly)2.50
PE ratio (TTM)N/A
EPS (TTM)-1.43
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est22.00
  • GlobeNewswire

    Caribou Biosciences to Participate in Upcoming Investor Conferences

    BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: Citi's 2024 Virtual Oncology Leadership SummitFebruary 21, 2024, fireside chat at 12:00 pm EST Leerink Global Biopharma ConferenceMarch 12, 2024, fireside chat at 1:40 pm EDT Barclays Global Healthcare ConferenceMarch 13, 2024 H.C. Wainwright 2nd An

  • Simply Wall St.

    Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

    Tim Kelly, chief technology officer, Caribou Biosciences Tim Kelly to lead Caribou’s technical operations strategy and execution -- Tim Kelly to lead Caribou’s technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate pivotal Phase 3 trial in 2L LBCL by YE 2024 -- -- CB-011 CaMMouflage Phase 1 trial enrolling patients at dose level 3; initial dose escalation data in r/r MM expected by YE 2